Month: January 2026

Jyske Bank expects a net profit of c. DKK 5.4bn in 2025, corresponding to earnings per share of c. DKK 85. Previously, expectations were for a net profit of DKK 4.9bn-5.3bn, corresponding to earnings per share of DKK 77-84. The improved outlook is driven by a broadly based positive development, supported by a high level of activity and favorable financial markets.Core profit and net profit for the period (DKKm) FY2025 FY2024 Index25/24 Q42025 Q32025 Q22025 Q12025 Q42025Net interest income 8,842 9,544 93 2,213 2,187 2,204 2,238 2,269Net fee and commission income 3,039 2,738 111 966 689 658 726 902Value adjustments 1,376 1,063 129 420 511 263 182 172Other income 300 180 167 98 33 118 51 12Income from operating lease (net) 97 168 58 15 19 31 32 31Core income 13,654 13,693 100 3,712 3,439 3,274 3,229 3,386Core expenses 6,591 6,402 103 1,859 1,537 1,662 1,533 1,634Core...

The upcoming fully electric version of the FX Super One MPV will offer the world’s first Super EAI F.A.C.E. System, which is not just a super LED display for the front fascia, but an EAI Avatar — an embodied co-pilot that is an extension of the driver. EAI F.A.C.E. continues to evolve in both hardware and software as it captured widespread attention during the CES time frame in Las Vegas earlier this month.LOS ANGELES, Jan. 13, 2026 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared additional details on its upcoming available F.A.C.E. System which stands for “Front AI Communication Ecosystem.” The F.A.C.E. System will be available as an option on the Company’s fully...

— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib and osimertinib combination approved in China in June 2025 — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) combination for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR tyrosine kinase...

TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) — In a release issued under the headline “Visionary Holdings Inc. Reports Fiscal Year 2025 Annual Report” on Monday, January 12th by Visionary Holdings Inc. (Nasdaq: GV), please be advised that the headline and content have been updated to accurately reflect comments from the U.S. Securities and Exchange Commission. The corrected release follows: Visionary Holdings Inc. Releases Final Fiscal Year 2025 Annual Report and Audited Financial Statements; Form 20-F Filing Pending  Highlighting Strategic Transformation and Early Commercial Progress in Emerging Health Businesses Visionary Holdings Inc. (Nasdaq: GV) (the “Company”) today announced the public release of its final annual report and audited financial statements for the fiscal year ended March 31, 2025. The Company has completed...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $5.59 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $30 million, before deducting placement agent fees and offering expenses. The Warrants included in the units have been approved for listing on the Nasdaq Capital Market and are expected to commence...

VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — NOVAGOLD RESOURCES INC. (“NOVAGOLD” or the “Company”) (NYSE American, TSX: NG) is pleased to announce the appointment of Frank Arcese as Project Director to Donlin Gold LLC (“Donlin Gold”), bringing more than four decades of global project leadership to Donlin Gold. This hiring further strengthens the team as we prepare to launch the work on the Bankable Feasibility Study (BFS) and progress the project toward development. Mr. Arcese has deep experience in the execution of large-scale mining capital projects in both the U.S. and international jurisdictions. Most recently, he served as Capital Projects Business Leader for North American mining operations at WSP Global Inc., an Engineering, Procurement, and Construction Management (EPCM) firm. Prior to that, he acted as...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — VR Resources Limited (“VR” or the “Company”, TSXV: VRR) announces that, in connection with its previously announced brokered private placement offering (the “Offering”) of up to 17,187,500 units (the “Units”) for aggregate gross proceeds of $2,750,000, the Company will complete its previously announced consolidation of its issued and outstanding common shares (“Common Shares”) on a basis of ten (10) pre-consolidation common shares for one (1) post-consolidation common share (the “Consolidation”), subject to approval of the TSX Venture Exchange (the “Exchange”). The Company currently has 133,443,467 Common Shares issued and outstanding, and it is anticipated that immediately...